The high prevalence of sarcopenia in patients with ovarian and endometrial cancers underscores the importance of early ...

The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, ...

PARKERSBURG, W.Va. (WTAP) - National Cancer Prevention Month encourages communities to educate themselves on what cancer is.

The use of The Cancer Genome Atlas molecular subgroups ... This suggests that the uterus may be a unique tumor-immune microenvironment and maybe chemotherapy plus immunotherapy is required for ...

“We are pleased that the FDA has designated our ACR-368 OncoSignature assay, developed specifically to prospectively predict tumor sensitivity ... patients with endometrial cancer,” said ...

A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new ...

The ACR-368-tailored OncoSignature assay is being used to identify patients most likely to respond to the company's lead drug candidate ACR-368 in an ongoing, registrational-intent, phase IIb trial in ...

A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new mothers, and it has potential with other cancers as well.

Lavanya (name changed), in her early 30s, recently came in for a routine health check-up. When her HPV DNA test came back ...

A new nanomedicine drug delivery system improves chemotherapy targeting for choriocarcinoma, shrinking tumors by 95% in mouse models. Researchers engineered polymersomes to enhance methotrexate (MTX) ...